{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/05/07/3289988/29489/en/AIM-ImmunoTech-Announces-50-Objective-Response-Rate-ORR-in-UPMC-Recurrent-Ovarian-Cancer-Phase-2-Clinical-Trial-Suggesting-Breakthrough-Combination-Potential.html", "message": "News view counter 709832 successfully enlarged"}